

SAFETY DATA SHEET FOR Qnostics MYCOBACTERIUM TUBERCULOSIS (MTB)

1. Product and Company Identification

Product Name:

Product range could including:

- MTB-Analytical 'Q' Panels (AQP)
- MTB -Dilution Panels (DP)
- MTB -Molecular 'Q' Panels (MQP)
- MTB - 'Q' Controls (QC)
- MTB -Evaluation Panels (EP)
- MTB -Mini-Panels (MP)
- MTB -Positive Controls (PC)

Date of Compilation: 10th of July 2020

Document Reference: RPBL3034_Rev02



Supplied by:

Qnostics Ltd
Block 1
Todd Campus
West of Scotland Science Park
Glasgow
G20 0XA
United Kingdom

Emergency Tel: 0141 946 4207 (Mon-Fri: 09:00-17:00)

Email: info@qnostics.com

Intended Use: For research use only, not for in vitro diagnostic procedures

Description: Simulated clinical specimens and artificial sputum for the molecular detection of MTB.

2. Hazards Identification

Not a hazardous substance according to regulation (EC) No 1272/2008.

3. Composition/information on ingredients

No components need to be disclosed according to the applicable regulations.

4. First Aid Measures



If accidental contact with material occurs laboratory staff must follow local first aid procedures that are normally applied following exposure to an equivalent clinical specimen. Following exposure medical advice should be sought.

5. Fire Fighting Measures

Not applicable.

6. Accidental Release Measures

Cover the area with absorbent paper/material and flood with a suitable disinfectant. The area must be left undisturbed for thirty minutes before the spill is mopped up with excess of absorbent paper. Transfer all waste to a biological waste bin for incineration

7. Handling and storage

Store at $\leq -20^{\circ}\text{C}$. For inactivation, the vaccine strain *M. bovis* has been heat treated (20mins @ 80°C). The *M. tuberculosis* material has been gamma irradiated. Samples must be processed in a laboratory environment which, as defined by the national regulations or guidelines, as suitable for the practice of clinical microbiology. Staff handling the material should be trained in the handling of biological material. The samples should be treated with the same degree of care as would be taken with equivalent clinical specimens. The panel is intended specifically for the purpose of quality surveillance of laboratory procedures where samples will be processed by staff trained to deal with infectious hazards associated with the handling of clinical material of unknown content.

8. Exposure Controls and Personal Protection

Use good laboratory practice and wear appropriate laboratory coats, gloves and eye protection.

9. Physical and Chemical properties

Frozen samples shipped on dry ice.

10. Stability and Reactivity

Storage is unlikely to increase or decrease the risks associated with handling the material.

11. Toxicological Information

Not applicable.

12. Ecological information

Not applicable.

13. Disposal Considerations

The used material must be disposed of using processes used for other clinical biological waste.

14. Transport Information

Refer to national and international regulations for the transport of biological specimens. This material is classed as UN3373- Biological Substance B

15. Regulatory Information

Note that this safety sheet does not constitute the user's own assessments of workplace risk as required by Health and Safety legislation.

16. Other Information

For further safety information concerning this product, participants are advised to read the instruction manual accompanying the panel.

This information is based on present knowledge and should only be used as a guide.